Compare BCAL & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCAL | STTK |
|---|---|---|
| Founded | 2001 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 704.1M | 652.4M |
| IPO Year | 2020 | 2020 |
| Metric | BCAL | STTK |
|---|---|---|
| Price | $21.86 | $5.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $24.75 | $15.40 |
| AVG Volume (30 Days) | 187.5K | ★ 1.2M |
| Earning Date | 10-30-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | ★ 777.27 | 53.02 |
| EPS | ★ 0.86 | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | $1.36 | N/A |
| Revenue Next Year | $6.48 | N/A |
| P/E Ratio | $25.20 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.61 | $1.72 |
| 52 Week High | $22.41 | $8.33 |
| Indicator | BCAL | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 52.76 | 37.90 |
| Support Level | $20.52 | $3.55 |
| Resistance Level | $21.87 | $7.66 |
| Average True Range (ATR) | 0.40 | 0.45 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 68.57 | 12.31 |
California BanCorp is a relationship-focused community bank offering commercial loan and deposit products, along with other services delivered directly or through strategic alliances, to business and individual customers in its target markets. The Company provides financial products and services to individuals, professionals, and small to medium-sized businesses through its branch and commercial banking offices serving California. Its lending products consist mainly of construction and land development loans, real estate loans, C&I loans, and consumer loans, and it is a Preferred SBA Lender, while its deposit products consist mainly of demand deposit, money market, and certificates of deposit. The Company operates in one reportable segment, commercial banking.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.